Description

Johnson & Johnson’s Innovative Medicine Pipeline Is Stacked—The Oncology Expansion That Could Surprise Investors!

Johnson & Johnson (JNJ) reported strong financial results for the fourth quarter and full year of 2025, emphasizing its continued growth trajectory in both the Innovative Medicine and MedTech segments. The company delivered 5.3% operational sales growth for the full year, reaching $94.2 billion, despite facing headwinds from the loss of exclusivity (LOE) of STELARA. This performance underscores Johnson & Johnson’s robust portfolio, which includes 28 platforms or products generating at least $1 billion in annual revenues, ensuring a diversified and resilient growth model. In the Innovative Medicine segment, Johnson & Johnson achieved operational sales growth of 5.3% with standout performances in Oncology and Immunology. The Oncology division saw a 21% increase, spearheaded by the solid performance of products like DARZALEX, which experienced a 22% growth, and CARVYKTI, which became the leading CAR-T therapy for multiple myeloma. In Immunology, TREMFYA exhibited impressive growth of 65.